10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial

Prospective Comparison of Outcomes with Azacitidine and Decitabine in AML Patients Ineligible for Intensive Chemotherapy

(2022) Amer M. Zeidan et al.   BLOOD

The Time Toxicity of Cancer Treatment

(2022) Arjun Gupta et al.   JOURNAL OF CLINICAL ONCOLOGY

Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis

(2022) Arnon Nagler et al.   CLINICAL CANCER RESEARCH

10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG

(2022) Fabio Efficace et al.   BLOOD

Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies

(2021) Julia Stomper et al.   LEUKEMIA

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy

(2021) Raphael Itzykson et al.   BLOOD

CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial

(2021) Jeffrey E Lancet et al.   Lancet Haematology

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

(2020) Courtney D DiNardo et al.   Lancet Haematology

Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS

(2020) Gerwin Huls et al.   Blood Advances

Decitabine induces gene derepression on monosomic chromosomes: in vitro and in vivo effects in adverse-risk cytogenetics AML

(2020) Gabriele Greve et al.   CANCER RESEARCH

Not type of induction therapy but consolidation with allogeneic hematopoietic cell transplantation determines outcome in older AML patients: a single center experience of 355 consecutive patients

(2019) Jacobien Hilberink et al.   LEUKEMIA RESEARCH

Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial

(2019) Michael Lübbert et al.   JOURNAL OF CLINICAL ONCOLOGY

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care

(2018) Hartmut Döhner et al.   LEUKEMIA

Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses

(2016) Marjan Cruijsen et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

Allogeneic hematopoietic cell transplantation with double alkylating agents containing reduced-intensity conditioning for patients ≥60 years with advanced AML/MDS

(2016) H Bertz et al.   LEUKEMIA

Targeting the cancer epigenome for therapy

(2016) Peter A. Jones et al.   NATURE REVIEWS GENETICS

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

(2016) John S. Welch et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acute Myeloid Leukemia

(2015) Hartmut Döhner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pretransplantation 5-Azacitidine in High-Risk Myelodysplastic Syndrome

(2014) Taiga Nishihori et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Clinical Results of Hypomethylating Agents in AML Treatment

(2014) Marjan Cruijsen et al.   Journal of Clinical Medicine

Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17)

(2013) Sergio Amadori et al.   JOURNAL OF CLINICAL ONCOLOGY

Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)

(2012) O. C. Goodyear et al.   BLOOD

When Azanucleoside Treatment Can Be Curative: Nonintensive Bridging Strategy Before Allografting in Older Patients With Myelodysplastic Syndrome/Acute Myeloid Leukemia

(2012) Michael Lübbert et al.   JOURNAL OF CLINICAL ONCOLOGY

Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia

(2012) Ellen K. Ritchie et al.   LEUKEMIA & LYMPHOMA

A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy

(2011) M. Lubbert et al.   HAEMATOLOGICA

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

(2010) W. Blum et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD